Prague 2012 Programme Hotels Exhibition Visa Information Satellite Meetings

Retropupillary fixated iris claw lens for aphakia subluxated IOLs and complicated cataract cases

Session Details

Session Title: Cataract II

Session Date/Time: Saturday 16/02/2013 | 08:30-11:00

Paper Time: 08:30

Venue: Hall 1

First Author: : T.Choragiewicz POLAND

Co Author(s): :    M. Szkaradek   R. Rejdak   A. Juenemann        

Abstract Details


Evaluation of safety, visual and refractive results of retropupillary fixated iris claw lens


Department of Ophthalmology of University Erlangen-Nuernberg, Germany


In this retrospective case series 22 eyes of 22 patients (mean age 75±11 years, 8 males, 14 females) were included, who underwent retropupillary implantation of iris-claw lens (Verisyse, AMO) at the Department of Ophthalmology of University Erlangen-Nuernberg between March 2007 and April 2010. IOL calculation was performed using IOL Master and Haigis formula. Data were collected retrospectively.


The mean follow up time was 13 month. Indications included primary iris-claw implantation during complicated cataract due to lens subluxation (PSX, FIS and posttraumatic) in 4 eyes, or secondary iris-claw lens implantation in aphakia (7 eyes) and posterior IOL subluxation (11 eyes). Mean BCVA improved by 4 Snellen’s lines (range from -2 to 19). In 5 eyes (23%) complications correlated with retropupillary iris-claw lens (oval iris, iris atrophy, IOL decentration and iridodonesis) occurred without influence on BCVA or IOP. During postoperative follow up only one eye with PSX glaucoma showed IOP measurements higher than 21 mmHg. In the end of follow-up mean IOP was 15±3 mmHg. Mean difference between target refraction and refractive result in spherical equivalent was 1.01 Dsph (min 0.01 Dsph, max 3.72 Dsph, SD 0.88).


Retropupillary fixated iris-claw lens (Verisyse) seems to be a safe method for correction in aphakia, subluxated IOLs and complicated cataract cases without intraoperative possibility of posterior chamber intracapsular lens implantation.

Financial Disclosure:


Back to Freepaper Session